News
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. announces CEO Lisa Conte's virtual presentations at upcoming conferences. The company focuses on developing plant-derived medicines for gastrointestinal distress -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present at H.C. Wainwright 27th Annual Global Investment Conference. Lisa Conte to discuss pharmaceutical developments for gastrointestinal distress -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Jaguar Health announces conditional FDA approval of Canalevia-CA1 for CID in dogs and strategic plans to expand indication for general diarrhea treatment globally. Participation in 2025 Animal Health Summit -
-
